Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Apr 06, 2018 10:03am
147 Views
Post# 27841973

Time: our best ally

Time: our best ally
I'm reading your posts on how TH is under-evaluated. Funny how everything at this time seems to go in that direction: even the 52yearLOW thats published (4,96) doesn't reflect the reality: lets see last year numbers at the same time:
04/06/2017 5.88 6.00 5.67 5.96 245,155 -0.12 -1.97% 5.96 1.44m 439
04/05/2017 5.98 6.16 5.98 6.08 158,262 0.11 1.84% 6.08 965.29k 333
04/04/2017 5.96 5.98 5.88 5.97 172,822 -0.03 -0.50% 5.97 1.03m 340
04/03/2017 6.15 6.17 5.91 6.00 228,205 -0.15 -2.44% 6.00 1.37m 416
03/31/2017 6.24 6.24 6.05 6.15 187,442 0.01 0.16% 6.15 1.15m 354
03/30/2017 5.95 6.23 5.93 6.14 335,858 0.20 3.37% 6.14 2.05m 484
03/29/2017 5.70 6.00 5.61 5.94 286,753 0.25 4.39% 5.94 1.67m 536
03/28/2017 5.75 5.78 5.62 5.69 97,163 -0.09 -1.56% 5.69 554.57k 296
03/27/2017 5.71 5.81 5.51 5.78 143,728 -0.02 -0.34% 5.78 821.28k 293

And finally, what about the charts telling us that in july (when TH will share with us the second quarter result....and first sales for TROGARZO) the 52 year low will be around 8$ a share.......
YOU REALLY THINK WE WILL BE SITTING AT 9$ a share with analysts staying stuck up with a 11,50 $ price target........Dont think so......

FTV.
Bullboard Posts